首页 > 最新文献

Journal of VitreoRetinal Diseases最新文献

英文 中文
Unexplained Acute Total Loss of Vision After Primary Scleral Buckle Surgery. 原发性巩膜扣带手术后不明原因的急性视力完全丧失。
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-06-22 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241260483
Greg Budoff, Alexander B Dillon, Adrian Au, Allan E Krieger, Steven D Schwartz

Purpose: To present 2 cases of acute total loss of vision after scleral buckle surgery for rhegmatogenous retinal detachment. Methods: A retrospective chart review of 2 cases and an analysis of the literature were performed. Results: An 18-year-old woman and a 67-year-old woman suffered complete loss of vision in their operative eye after primary scleral buckle surgery with encircling bands. Conclusions: Profound ocular ischemia resulting in total acute vision loss is a rare and devastating outcome of primary scleral buckle procedures and may be caused by strangulation of the eye with an encircling band. Attention paid to the key tenets of this often successful and useful surgical technique may lower the risk for this complication.

目的:介绍 2 例流变性视网膜脱离巩膜扣带手术后急性完全丧失视力的病例。方法:对 2 例病例进行回顾性病历审查和文献分析:对 2 例病例进行回顾性病历审查,并对文献进行分析。结果一名 18 岁的女性和一名 67 岁的女性在使用环形带进行初级巩膜扣带手术后,术眼视力完全丧失。得出结论:眼球严重缺血导致急性视力完全丧失是初级巩膜扣带手术罕见的破坏性结果,可能是由于眼球被包围带勒伤所致。注意这种通常很成功、很有用的手术技术的关键原则,可以降低发生这种并发症的风险。
{"title":"Unexplained Acute Total Loss of Vision After Primary Scleral Buckle Surgery.","authors":"Greg Budoff, Alexander B Dillon, Adrian Au, Allan E Krieger, Steven D Schwartz","doi":"10.1177/24741264241260483","DOIUrl":"https://doi.org/10.1177/24741264241260483","url":null,"abstract":"<p><p><b>Purpose:</b> To present 2 cases of acute total loss of vision after scleral buckle surgery for rhegmatogenous retinal detachment. <b>Methods:</b> A retrospective chart review of 2 cases and an analysis of the literature were performed. <b>Results:</b> An 18-year-old woman and a 67-year-old woman suffered complete loss of vision in their operative eye after primary scleral buckle surgery with encircling bands. <b>Conclusions:</b> Profound ocular ischemia resulting in total acute vision loss is a rare and devastating outcome of primary scleral buckle procedures and may be caused by strangulation of the eye with an encircling band. Attention paid to the key tenets of this often successful and useful surgical technique may lower the risk for this complication.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 5","pages":"600-604"},"PeriodicalIF":0.5,"publicationDate":"2024-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418699/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multimodal Imaging of Unilateral Benign Yellow Dot Maculopathy. 单侧良性黄斑病变的多模态成像
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-06-16 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241260489
Michael Balas, Jovi Wong, Parnian Arjmand

Purpose: To describe the multimodal imaging findings associated with benign yellow dot maculopathy. Methods: A case report was analyzed. Results: A healthy 42-year-old White man was evaluated after several weeks of photopsias and an inferior retinal tear in the right eye. The tear was treated with laser retinopexy. A fundus examination showed numerous small, yellow, subretinal lesions in and around the macula of the right eye only. The patient had no known systemic conditions and an unremarkable family and ocular history, with 20/20 visual acuity in both eyes. Multimodal imaging findings were consistent with the newly described phenotype of benign yellow dot maculopathy. Conclusions: This is the second known case of unilateral benign yellow dot maculopathy. Distinct multimodal imaging findings between unilateral cases and bilateral cases may suggest differences in their etiology and manifestation.

目的:描述与良性黄斑点状病变相关的多模态成像结果。方法:分析一份病例报告:对一份病例报告进行分析。结果:一名 42 岁的健康白人男子在数周的光斑和右眼视网膜下部撕裂后接受了评估。他接受了激光视网膜手术治疗。眼底检查显示,仅右眼黄斑部及周围有许多黄色的小视网膜下病变。患者没有已知的全身性疾病,家族史和眼科病史均无异常,双眼视力均为 20/20。多模态成像结果与新描述的良性黄斑点状病变表型一致。结论:这是已知的第二例单侧良性黄斑点状病变。单侧病例与双侧病例不同的多模态成像结果可能提示其病因和表现存在差异。
{"title":"Multimodal Imaging of Unilateral Benign Yellow Dot Maculopathy.","authors":"Michael Balas, Jovi Wong, Parnian Arjmand","doi":"10.1177/24741264241260489","DOIUrl":"https://doi.org/10.1177/24741264241260489","url":null,"abstract":"<p><p><b>Purpose:</b> To describe the multimodal imaging findings associated with benign yellow dot maculopathy. <b>Methods:</b> A case report was analyzed. <b>Results:</b> A healthy 42-year-old White man was evaluated after several weeks of photopsias and an inferior retinal tear in the right eye. The tear was treated with laser retinopexy. A fundus examination showed numerous small, yellow, subretinal lesions in and around the macula of the right eye only. The patient had no known systemic conditions and an unremarkable family and ocular history, with 20/20 visual acuity in both eyes. Multimodal imaging findings were consistent with the newly described phenotype of benign yellow dot maculopathy. <b>Conclusions:</b> This is the second known case of unilateral benign yellow dot maculopathy. Distinct multimodal imaging findings between unilateral cases and bilateral cases may suggest differences in their etiology and manifestation.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 5","pages":"597-599"},"PeriodicalIF":0.5,"publicationDate":"2024-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Horseshoe Retinal Tear Minutes After Use of a New Pilocarpine Formulation in a Presbyopic, Emmetropic Man. 一名老花眼患者在使用新型匹洛卡品制剂数分钟后出现马蹄形视网膜撕裂。
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-05-31 DOI: 10.1177/24741264241255589
Isabel C Eaddy, Obadah Moushmoush, Omar Sabbagh, Muhi Dean Barazi, Osama Sabbagh

Purpose: To examine the risks associated with the use of pilocarpine hydrochloride 1.25% ophthalmic solution prescribed for presbyopia. Methods: The adverse ocular events reported after the use of pilocarpine were compared with the symptoms experienced by a 62-year-old presbyopic man shortly after taking pilocarpine. Results: The patient reported symptoms soon after instilling pilocarpine, including eye pain, hazy vision, and floaters. An examination showed a horseshoe retinal tear, vitreous hemorrhage, and posterior vitreous detachment, for which the patient received extensive clinical and surgical management. Conclusions: This case highlights the need for comprehensive eye examinations and patient education about the warning signs of retinal tears or detachments before prescribing pilocarpine for presbyopia. Vigilance regarding the potential rare adverse effects of this new pilocarpine ophthalmic solution is warranted.

目的:研究使用盐酸匹罗卡品 1.25%眼药水治疗老花眼的相关风险。方法:使用盐酸皮洛卡品 1.25%眼药水治疗老花眼:将一位 62 岁的老花眼男性在使用皮洛卡品后不久出现的症状与使用皮洛卡品后报告的眼部不良事件进行比较。结果:该患者在注射皮洛卡品后不久就出现了症状,包括眼痛、视力模糊和眼球浮动。检查显示马蹄形视网膜撕裂、玻璃体出血和玻璃体后脱离,患者接受了大量临床和手术治疗。结论:本病例强调,在开具皮洛卡品治疗老花眼的处方之前,需要进行全面的眼科检查,并对患者进行视网膜撕裂或脱离警示信号的教育。对于这种新的皮洛卡品眼药水可能出现的罕见不良反应,应保持警惕。
{"title":"Horseshoe Retinal Tear Minutes After Use of a New Pilocarpine Formulation in a Presbyopic, Emmetropic Man.","authors":"Isabel C Eaddy, Obadah Moushmoush, Omar Sabbagh, Muhi Dean Barazi, Osama Sabbagh","doi":"10.1177/24741264241255589","DOIUrl":"10.1177/24741264241255589","url":null,"abstract":"<p><p><b>Purpose:</b> To examine the risks associated with the use of pilocarpine hydrochloride 1.25% ophthalmic solution prescribed for presbyopia. <b>Methods:</b> The adverse ocular events reported after the use of pilocarpine were compared with the symptoms experienced by a 62-year-old presbyopic man shortly after taking pilocarpine. <b>Results:</b> The patient reported symptoms soon after instilling pilocarpine, including eye pain, hazy vision, and floaters. An examination showed a horseshoe retinal tear, vitreous hemorrhage, and posterior vitreous detachment, for which the patient received extensive clinical and surgical management. <b>Conclusions:</b> This case highlights the need for comprehensive eye examinations and patient education about the warning signs of retinal tears or detachments before prescribing pilocarpine for presbyopia. Vigilance regarding the potential rare adverse effects of this new pilocarpine ophthalmic solution is warranted.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":" ","pages":"24741264241255589"},"PeriodicalIF":0.5,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11562214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142648078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Faricimab-Associated Retinal Vasculitis. 法尼单抗相关视网膜血管炎。
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-05-29 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241253899
Mohammad Z Siddiqui, Alia Durrani, Bradley T Smith

Purpose: To report a case of retinal vasculitis after intravitreal faricimab-svoa injection. Methods: A case and its management were reviewed. Results: A 77-year-old woman presented with a painless decrease in visual acuity (VA) to counting fingers after receiving an intravitreal faricimab-svoa injection for neovascular age-related macular degeneration. An examination showed an anterior chamber reaction without hypopyon. Vitritis was present with numerous scattered retinal hemorrhages. Fluorescein angiography showed delayed filling with extensive vascular leakage consistent with nonocclusive vasculitis. The patient was immediately treated with intravenous steroids, resulting in rapid improvement and recovery of her 20/40 baseline VA. The vasculitis resolved without occlusion. Conclusions: Faricimab-svoa can be associated with significant vasculitis. Prompt treatment with intravenous steroids can be beneficial in the recovery of sight.

目的:报告一例玻璃体内注射法尼单抗-voa 后发生视网膜血管炎的病例。方法:回顾一例病例及其处理。结果一名 77 岁的妇女因新生血管性老年黄斑变性接受了玻璃体内法尼单抗-voa 注射治疗,随后出现无痛性视力下降,只能数手指。检查显示前房有反应,但无眼睑下垂。玻璃体炎伴有大量散在视网膜出血。荧光素血管造影显示充盈延迟,并伴有广泛的血管渗漏,与非闭塞性脉管炎一致。患者立即接受了静脉类固醇治疗,结果病情迅速好转,恢复了 20/40 的基线视力。脉管炎在没有闭塞的情况下得到缓解。结论Faricimab-svoa 可导致严重的血管炎。及时使用静脉类固醇治疗有助于恢复视力。
{"title":"Faricimab-Associated Retinal Vasculitis.","authors":"Mohammad Z Siddiqui, Alia Durrani, Bradley T Smith","doi":"10.1177/24741264241253899","DOIUrl":"https://doi.org/10.1177/24741264241253899","url":null,"abstract":"<p><p><b>Purpose:</b> To report a case of retinal vasculitis after intravitreal faricimab-svoa injection. <b>Methods:</b> A case and its management were reviewed. <b>Results:</b> A 77-year-old woman presented with a painless decrease in visual acuity (VA) to counting fingers after receiving an intravitreal faricimab-svoa injection for neovascular age-related macular degeneration. An examination showed an anterior chamber reaction without hypopyon. Vitritis was present with numerous scattered retinal hemorrhages. Fluorescein angiography showed delayed filling with extensive vascular leakage consistent with nonocclusive vasculitis. The patient was immediately treated with intravenous steroids, resulting in rapid improvement and recovery of her 20/40 baseline VA. The vasculitis resolved without occlusion. <b>Conclusions:</b> Faricimab-svoa can be associated with significant vasculitis. Prompt treatment with intravenous steroids can be beneficial in the recovery of sight.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 5","pages":"627-630"},"PeriodicalIF":0.5,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intraoperative OCT-Guided Volumetric Measurements of Subretinal Therapy Delivery in Humans. 术中 OCT 引导下的人体视网膜下治疗容积测量。
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-05-29 eCollection Date: 2024-09-01 DOI: 10.1177/24741264241253920
Nita G Valikodath, Jianwei D Li, William Raynor, Joseph A Izatt, Cynthia A Toth, Lejla Vajzovic

Purpose: To evaluate a recently developed technique using intraoperative optical coherence tomography (OCT) to measure subretinal tissue plasminogen activator (tPA) volumes in patients with submacular hemorrhage secondary to exudative age-related macular degeneration (AMD). Methods: Three patients (72 to 83 years old) had 25-gauge pars plana vitrectomy, subretinal tPA, and a partial gas fill. An investigational intraoperative OCT system with a modified widefield noncontact indirect viewing apparatus was used to image subretinal tPA blebs. Using the recently developed technique, the volume and surface area in the segmented region of interest were determined. Results: In each case, the delivered tPA volume measured from the syringe differed from the intraoperative OCT-measured subretinal tPA volume: Patient 1, 130 µL from syringe, 118 µL based on intraoperative OCT, 9% difference; Patient 2, 140 µL, 50 µL, 64%; Patient 3, 110 µL, 122 µL, 11%. The total bleb surface area was 129 mm2 in Patient 1, 55 mm2 in Patient 2, and 106 mm2 in Patient 3. Conclusions: This was the first human study to implement and evaluate intraoperative OCT image-based methods to obtain volumetric bleb measurements in patients receiving subretinal tPA for exudative AMD. This proof-of-concept study showed that intraoperative OCT-obtained bleb volume differed from intraoperative recordings, which could be explained by tPA delivery into the vitreous, efflux through the retinotomy, or human error. Intraoperative OCT can provide visualization and quantification of subretinal tPA bleb volume and surface area, which has implications for improved safety, efficacy, and analysis of the effects of subretinal drug delivery.

目的:评估一种最新开发的技术,该技术利用术中光学相干断层扫描(OCT)测量渗出性年龄相关性黄斑变性(AMD)继发性黄斑下出血患者的视网膜下组织纤溶酶原激活剂(tPA)容量。测量方法三名患者(72 至 83 岁)接受了 25 号玻璃体旁切除术、视网膜下 tPA 和部分气体填充。研究人员使用带改良宽视场非接触式间接观察装置的术中 OCT 系统对视网膜下 tPA 泡进行成像。利用最近开发的技术,确定了感兴趣区段的体积和表面积。结果显示在每个病例中,从注射器中测得的 tPA 容量与术中 OCT 测得的视网膜下 tPA 容量不同:患者 1 的注射器注射量为 130 µL,术中 OCT 测量值为 118 µL,两者相差 9%;患者 2 的注射器注射量为 140 µL,术中 OCT 测量值为 50 µL,两者相差 64%;患者 3 的注射器注射量为 110 µL,术中 OCT 测量值为 122 µL,两者相差 11%。患者 1 的眼泡总表面积为 129 平方毫米,患者 2 为 55 平方毫米,患者 3 为 106 平方毫米。结论:这是第一项对接受视网膜下 tPA 治疗渗出性 AMD 的患者进行术中 OCT 图像测量眼泡体积的方法进行实施和评估的人体研究。这项概念验证研究表明,术中 OCT 获得的眼泡体积与术中记录不同,这可能是由于 tPA 被输送到玻璃体内、通过视网膜切口外流或人为失误造成的。术中 OCT 可提供视网膜下 tPA 眼泡体积和表面积的可视化和量化,这对提高安全性、有效性和分析视网膜下给药的效果具有重要意义。
{"title":"Intraoperative OCT-Guided Volumetric Measurements of Subretinal Therapy Delivery in Humans.","authors":"Nita G Valikodath, Jianwei D Li, William Raynor, Joseph A Izatt, Cynthia A Toth, Lejla Vajzovic","doi":"10.1177/24741264241253920","DOIUrl":"https://doi.org/10.1177/24741264241253920","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate a recently developed technique using intraoperative optical coherence tomography (OCT) to measure subretinal tissue plasminogen activator (tPA) volumes in patients with submacular hemorrhage secondary to exudative age-related macular degeneration (AMD). <b>Methods:</b> Three patients (72 to 83 years old) had 25-gauge pars plana vitrectomy, subretinal tPA, and a partial gas fill. An investigational intraoperative OCT system with a modified widefield noncontact indirect viewing apparatus was used to image subretinal tPA blebs. Using the recently developed technique, the volume and surface area in the segmented region of interest were determined. <b>Results:</b> In each case, the delivered tPA volume measured from the syringe differed from the intraoperative OCT-measured subretinal tPA volume: Patient 1, 130 µL from syringe, 118 µL based on intraoperative OCT, 9% difference; Patient 2, 140 µL, 50 µL, 64%; Patient 3, 110 µL, 122 µL, 11%. The total bleb surface area was 129 mm<sup>2</sup> in Patient 1, 55 mm<sup>2</sup> in Patient 2, and 106 mm<sup>2</sup> in Patient 3. <b>Conclusions:</b> This was the first human study to implement and evaluate intraoperative OCT image-based methods to obtain volumetric bleb measurements in patients receiving subretinal tPA for exudative AMD. This proof-of-concept study showed that intraoperative OCT-obtained bleb volume differed from intraoperative recordings, which could be explained by tPA delivery into the vitreous, efflux through the retinotomy, or human error. Intraoperative OCT can provide visualization and quantification of subretinal tPA bleb volume and surface area, which has implications for improved safety, efficacy, and analysis of the effects of subretinal drug delivery.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 5","pages":"587-592"},"PeriodicalIF":0.5,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11418694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142349355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From the Editor-in-Chief. 主编的话
IF 0.6 Q4 OPHTHALMOLOGY Pub Date : 2024-05-17 eCollection Date: 2024-05-01 DOI: 10.1177/24741264241245781
Timothy G Murray
{"title":"From the Editor-in-Chief.","authors":"Timothy G Murray","doi":"10.1177/24741264241245781","DOIUrl":"https://doi.org/10.1177/24741264241245781","url":null,"abstract":"","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 3","pages":"227-230"},"PeriodicalIF":0.6,"publicationDate":"2024-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11102724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141071271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Google Trends-Assisted Analysis of the Readability, Accountability, and Accessibility of Online Patient Education Materials for the Treatment of AMD After US FDA Approval of Pegcetacoplan. 谷歌趋势辅助分析美国 FDA 批准 Pegcetacoplan 后治疗老年痴呆症的在线患者教育材料的可读性、责任性和可访问性。
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-04-30 eCollection Date: 2024-07-01 DOI: 10.1177/24741264241250156
Samuel A Cohen, Arthur Brant, Nadim Rayess, Ehsan Rahimy, Carolyn Pan, Ann Caroline Fisher, Suzann Pershing, Diana Do

Purpose: To evaluate the readability, accountability, accessibility, and source of online patient education materials for treatment of age-related macular degeneration (AMD) and to quantify public interest in Syfovre and geographic atrophy after US Food and Drug Administration (FDA) approval. Methods: Websites were classified into 4 categories by information source. Readability was assessed using 5 validated readability indices. Accountability was assessed using 4 benchmarks of the Journal of the American Medical Association (JAMA). Accessibility was evaluated using 3 established criteria. The Google Trends tool was used to evaluate temporal trends in public interest in "Syfovre" and "geographic atrophy" in the months after FDA approval. Results: Of 100 websites analyzed, 22% were written below the recommended sixth-grade reading level. The mean (±SD) grade level of analyzed articles was 9.76 ± 3.35. Websites averaged 1.40 ± 1.39 (of 4) JAMA accountability metrics. The majority of articles (67%) were from private practice/independent organizations. A significant increase in the public interest in the terms "Syfovre" and "geographic atrophy" after FDA approval was found with the Google Trends tool (P < .001). Conclusions: Patient education materials related to AMD treatment are often written at inappropriate reading levels and lack established accountability and accessibility metrics. Articles from national organizations ranked highest on accessibility metrics but were less visible on a Google search, suggesting the need for visibility-enhancing measures. Patient education materials related to the term "Syfovre" had the highest average reading level and low accountability, suggesting the need to modify resources to best address the needs of an increasingly curious public.

目的:评估治疗老年性黄斑变性(AMD)的在线患者教育材料的可读性、责任性、可及性和来源,并量化美国食品药品管理局(FDA)批准后公众对赛福瑞和地理萎缩的兴趣。方法:按信息来源将网站分为 4 类。使用 5 个经过验证的可读性指数对可读性进行评估。使用《美国医学会杂志》(JAMA)的 4 个基准对责任性进行评估。可访问性使用 3 个既定标准进行评估。谷歌趋势工具用于评估美国食品药品管理局(FDA)批准后几个月内公众对 "Syfovre "和 "地理萎缩 "兴趣的时间趋势。结果:在分析的 100 个网站中,22% 的网站内容低于建议的六年级阅读水平。分析文章的平均年级(±SD)为 9.76 ± 3.35。网站的《美国医学会杂志》责任指标平均为 1.40 ± 1.39(共 4 项)。大多数文章(67%)来自私人诊所/独立机构。谷歌趋势工具发现,在美国食品药品管理局批准后,公众对 "Syfovre "和 "地理萎缩 "这两个词的兴趣明显增加(P 结论):与老年性视网膜病变治疗相关的患者教育材料通常以不恰当的阅读水平编写,缺乏既定的责任和可及性指标。国家组织的文章在可访问性指标上排名最高,但在谷歌搜索中的可见度较低,这表明需要采取提高可见度的措施。与 "Syfovre "一词相关的患者教育材料的平均阅读水平最高,但可问责性较低,这表明有必要修改资源,以最好地满足日益好奇的公众的需求。
{"title":"Google Trends-Assisted Analysis of the Readability, Accountability, and Accessibility of Online Patient Education Materials for the Treatment of AMD After US FDA Approval of Pegcetacoplan.","authors":"Samuel A Cohen, Arthur Brant, Nadim Rayess, Ehsan Rahimy, Carolyn Pan, Ann Caroline Fisher, Suzann Pershing, Diana Do","doi":"10.1177/24741264241250156","DOIUrl":"10.1177/24741264241250156","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate the readability, accountability, accessibility, and source of online patient education materials for treatment of age-related macular degeneration (AMD) and to quantify public interest in Syfovre and geographic atrophy after US Food and Drug Administration (FDA) approval. <b>Methods:</b> Websites were classified into 4 categories by information source. Readability was assessed using 5 validated readability indices. Accountability was assessed using 4 benchmarks of the <i>Journal of the American Medical Association</i> (<i>JAMA</i>). Accessibility was evaluated using 3 established criteria. The Google Trends tool was used to evaluate temporal trends in public interest in \"Syfovre\" and \"geographic atrophy\" in the months after FDA approval. <b>Results:</b> Of 100 websites analyzed, 22% were written below the recommended sixth-grade reading level. The mean (±SD) grade level of analyzed articles was 9.76 ± 3.35. Websites averaged 1.40 ± 1.39 (of 4) <i>JAMA</i> accountability metrics. The majority of articles (67%) were from private practice/independent organizations. A significant increase in the public interest in the terms \"Syfovre\" and \"geographic atrophy\" after FDA approval was found with the Google Trends tool (<i>P</i> < .001). <b>Conclusions:</b> Patient education materials related to AMD treatment are often written at inappropriate reading levels and lack established accountability and accessibility metrics. Articles from national organizations ranked highest on accessibility metrics but were less visible on a Google search, suggesting the need for visibility-enhancing measures. Patient education materials related to the term \"Syfovre\" had the highest average reading level and low accountability, suggesting the need to modify resources to best address the needs of an increasingly curious public.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 4","pages":"421-427"},"PeriodicalIF":0.5,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Serial Intravitreal Methotrexate Injections to Combat Recurrent Proliferative Vitreoretinopathy in a Pediatric Patient. 连续进行玻璃体内甲氨蝶呤注射治疗小儿复发性增殖性玻璃体视网膜病变
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-04-29 eCollection Date: 2024-07-01 DOI: 10.1177/24741264241249060
George Jiao, Philip J Ferrone

Purpose: To describe the use of serial intravitreal methotrexate to combat proliferative vitreoretinopathy (PVR) in a pediatric patient with recurrent retinal detachment (RD). Methods: A retrospective case analysis was performed. Results: A 6-year-old patient with bilateral panuveitis presented with recurrent RD in the right eye. After treatment with 2 RD surgeries performed elsewhere, the patient developed PVR that necessitated 5 additional surgeries for recurrent detachment. The patient subsequently received a total of 8 injections of methotrexate 400 µg/0.1 mL (0.1 mL) in the operating room at 1- to 2-week intervals over a 3-month period. Through 13 months of follow-up after the first methotrexate injection, there was no evidence of recurrent RD, PVR, or epiretinal membrane formation. Conclusions: Frequent serial intravitreal methotrexate injections apparently played a role in preventing recurrent PVR formation in this pediatric patient with a history of intraocular inflammation and recurrent RD.

目的:描述在一名复发性视网膜脱离(RD)的儿童患者中使用连续玻璃体内甲氨蝶呤治疗增殖性玻璃体视网膜病变(PVR)的情况。方法:进行回顾性病例分析:进行回顾性病例分析。结果一名患有双侧泛葡萄膜炎的 6 岁患者右眼复发性视网膜脱离。在其他地方进行了 2 次 RD 手术治疗后,患者出现了 PVR,需要再进行 5 次手术治疗复发性脱落。随后,患者在手术室接受了 8 次甲氨蝶呤 400 µg/0.1 mL(0.1 mL)注射,每次间隔 1 到 2 周,为期 3 个月。在第一次注射甲氨蝶呤后的 13 个月随访中,没有发现复发性 RD、PVR 或视网膜外膜形成的迹象。结论是在这名有眼内炎症和复发性 RD 病史的儿童患者身上,频繁连续的玻璃体内注射甲氨蝶呤显然在防止复发性 PVR 形成方面发挥了作用。
{"title":"Serial Intravitreal Methotrexate Injections to Combat Recurrent Proliferative Vitreoretinopathy in a Pediatric Patient.","authors":"George Jiao, Philip J Ferrone","doi":"10.1177/24741264241249060","DOIUrl":"10.1177/24741264241249060","url":null,"abstract":"<p><p><b>Purpose:</b> To describe the use of serial intravitreal methotrexate to combat proliferative vitreoretinopathy (PVR) in a pediatric patient with recurrent retinal detachment (RD). <b>Methods:</b> A retrospective case analysis was performed. <b>Results:</b> A 6-year-old patient with bilateral panuveitis presented with recurrent RD in the right eye. After treatment with 2 RD surgeries performed elsewhere, the patient developed PVR that necessitated 5 additional surgeries for recurrent detachment. The patient subsequently received a total of 8 injections of methotrexate 400 µg/0.1 mL (0.1 mL) in the operating room at 1- to 2-week intervals over a 3-month period. Through 13 months of follow-up after the first methotrexate injection, there was no evidence of recurrent RD, PVR, or epiretinal membrane formation. <b>Conclusions:</b> Frequent serial intravitreal methotrexate injections apparently played a role in preventing recurrent PVR formation in this pediatric patient with a history of intraocular inflammation and recurrent RD.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 4","pages":"452-456"},"PeriodicalIF":0.5,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141986713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autosomal Recessive ADAMTSL4-Related Isolated Ectopia Lentis in the Ohio Old Order Amish and Mennonite Communities. 俄亥俄州旧教派阿米什人和门诺人社区中与常染色体隐性遗传 ADAMTSL4 相关的孤立性大肛门外翻。
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-04-29 eCollection Date: 2024-07-01 DOI: 10.1177/24741264241249024
TsunKang Chiang, Amy Kloosterboer, Faruk Örge, Warren Sobol, Jose J Echegaray

Purpose: To present a series of 4 patients from the Ohio Amish or Mennonite populations with isolated ectopia lentis. Methods: A case series was evaluated. Results: Four cases with bilateral lens subluxations were diagnosed with a homozygous c.767_786del pathogenic variant in ADAMTSL4. Their ages ranged from 2 to 22 years. Three cases were symptomatic and were managed surgically with lensectomy, vitrectomy, and endolaser photocoagulation with or without secondary intraocular lens (IOL) implantation. One asymptomatic patient was observed. The postoperative visual acuity ranged from 20/20 to 20/60 in nonamblyopic eyes. Conclusions: The pathogenic homozygous c.767_786del variant in ADAMTSL4 may be a cause of bilateral isolated ectopia lentis in the Ohio Amish and Mennonite populations, likely as a result of a founder effect. Vitrectomy and lens extraction with or without secondary IOL implantation may lead to good visual outcomes. There were no cases of retinal detachment.

目的:介绍俄亥俄州阿米什人或门诺人中 4 例孤立性眼睑外翻患者的系列病例。方法:对一系列病例进行评估:对一系列病例进行评估。结果:四例双侧晶状体半脱位患者被确诊为 ADAMTSL4 中的同源 c.767_786del 致病变异体。他们的年龄从 2 岁到 22 岁不等。其中三例患者无症状,接受了晶状体切除术、玻璃体切除术和内激光光凝术,并植入或不植入二次眼内晶体(IOL)。还观察到一名无症状患者。非弱视眼的术后视力从 20/20 到 20/60 不等。结论ADAMTSL4 中的致病性同源 c.767_786del 变异可能是俄亥俄州阿米什人和门诺人中双侧孤立性有晶体眼病的病因,这很可能是创始效应的结果。进行玻璃体切除术和晶状体摘除术,同时植入或不植入二次人工晶体,可获得良好的视觉效果。没有视网膜脱离病例。
{"title":"Autosomal Recessive <i>ADAMTSL4</i>-Related Isolated Ectopia Lentis in the Ohio Old Order Amish and Mennonite Communities.","authors":"TsunKang Chiang, Amy Kloosterboer, Faruk Örge, Warren Sobol, Jose J Echegaray","doi":"10.1177/24741264241249024","DOIUrl":"10.1177/24741264241249024","url":null,"abstract":"<p><p><b>Purpose:</b> To present a series of 4 patients from the Ohio Amish or Mennonite populations with isolated ectopia lentis. <b>Methods:</b> A case series was evaluated. <b>Results:</b> Four cases with bilateral lens subluxations were diagnosed with a homozygous c.767_786del pathogenic variant in <i>ADAMTSL4</i>. Their ages ranged from 2 to 22 years. Three cases were symptomatic and were managed surgically with lensectomy, vitrectomy, and endolaser photocoagulation with or without secondary intraocular lens (IOL) implantation. One asymptomatic patient was observed. The postoperative visual acuity ranged from 20/20 to 20/60 in nonamblyopic eyes. <b>Conclusions:</b> The pathogenic homozygous c.767_786del variant in <i>ADAMTSL4</i> may be a cause of bilateral isolated ectopia lentis in the Ohio Amish and Mennonite populations, likely as a result of a founder effect. Vitrectomy and lens extraction with or without secondary IOL implantation may lead to good visual outcomes. There were no cases of retinal detachment.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 4","pages":"442-451"},"PeriodicalIF":0.5,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis. 脉络膜上腔给药治疗非感染性葡萄膜炎引起的黄斑水肿
IF 0.5 Q4 OPHTHALMOLOGY Pub Date : 2024-04-25 eCollection Date: 2024-07-01 DOI: 10.1177/24741264241246314
Ye Huang, Charlene Choo, Shelley Hancock, Thomas A Ciulla, Charles C Wykoff, Jessica G Shantha, Steven Yeh

Purpose: To evaluate clinical trials in the literature that focus on suprachoroidal drug delivery for the treatment of noninfectious uveitis and other posterior segment diseases. Methods: A synthesis of the literature was performed. Results: In 2021, suprachoroidal space triamcinolone acetonide, a corticosteroid delivery system used for the treatment of uveitic macular edema (ME), was approved by the US Food and Drug Administration. The drug-delivery system targets the suprachoroidal space using a microneedle-based device and has a favorable pharmacokinetic profile. Suprachoroidally administered investigational therapies have also been assessed in clinical trials for other posterior segment diseases, including diabetic ME, retinal vein occlusion, age-related macular degeneration, and choroidal melanoma. Conclusions: The safety and efficacy of suprachoroidal corticosteroid injections to treat uveitic ME have been shown in recent phase III clinical trials. Multiple programs are also investigating this modality of drug delivery for use in many other retinal and choroidal pathologies.

目的:评估文献中以脉络膜上腔给药治疗非感染性葡萄膜炎和其他后节疾病为重点的临床试验。方法:进行文献综述:对文献进行综述。结果2021 年,美国食品和药物管理局批准了用于治疗葡萄膜炎性黄斑水肿(ME)的皮质类固醇给药系统--脉络膜上腔曲安奈德。该给药系统使用微针装置靶向脉络膜上腔,具有良好的药代动力学特征。脉络膜上给药研究疗法也已在其他后节疾病的临床试验中进行了评估,包括糖尿病视网膜静脉闭塞、老年性黄斑变性和脉络膜黑色素瘤。结论最近的III期临床试验显示,脉络膜上皮质类固醇注射治疗葡萄膜炎ME具有安全性和有效性。多个项目也在研究这种给药方式在许多其他视网膜和脉络膜病症中的应用。
{"title":"Suprachoroidal Drug Delivery for Macular Edema Associated With Noninfectious Uveitis.","authors":"Ye Huang, Charlene Choo, Shelley Hancock, Thomas A Ciulla, Charles C Wykoff, Jessica G Shantha, Steven Yeh","doi":"10.1177/24741264241246314","DOIUrl":"10.1177/24741264241246314","url":null,"abstract":"<p><p><b>Purpose:</b> To evaluate clinical trials in the literature that focus on suprachoroidal drug delivery for the treatment of noninfectious uveitis and other posterior segment diseases. <b>Methods:</b> A synthesis of the literature was performed. <b>Results:</b> In 2021, suprachoroidal space triamcinolone acetonide, a corticosteroid delivery system used for the treatment of uveitic macular edema (ME), was approved by the US Food and Drug Administration. The drug-delivery system targets the suprachoroidal space using a microneedle-based device and has a favorable pharmacokinetic profile. Suprachoroidally administered investigational therapies have also been assessed in clinical trials for other posterior segment diseases, including diabetic ME, retinal vein occlusion, age-related macular degeneration, and choroidal melanoma. <b>Conclusions:</b> The safety and efficacy of suprachoroidal corticosteroid injections to treat uveitic ME have been shown in recent phase III clinical trials. Multiple programs are also investigating this modality of drug delivery for use in many other retinal and choroidal pathologies.</p>","PeriodicalId":17919,"journal":{"name":"Journal of VitreoRetinal Diseases","volume":"8 4","pages":"401-409"},"PeriodicalIF":0.5,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11323513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141988225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of VitreoRetinal Diseases
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1